QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=C1A62CE3455E97C87B6E5FC8388D846F;jsessionid=4BCCC9F0EC33103311475DC571D6E95B;jsessionid=1C5273C13B5290BA18DC6390644F5D7B;jsessionid=80B49F539B40566F22D95514ADCF9B41;jsessionid=DF8B0486E9633DA06A60222A6311E6A8;jsessionid=387F84A7C5A2CC669F4E8F28A31228AF;jsessionid=E44A8715662803A8A595522643F7EFD6;jsessionid=754949FDBC5354C259EB24C34DD71D34;jsessionid=682A0ED56812596DDFB06E666BAE2186 (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=9A293F9B4FD554D3CFAA1B9898B171E8;jsessionid=C8B5755C1AB667BEC9CC28337B057DA7;jsessionid=C1A62CE3455E97C87B6E5FC8388D846F;jsessionid=4BCCC9F0EC33103311475DC571D6E95B;jsessionid=1C5273C13B5290BA18DC6390644F5D7B;jsessionid=80B49F539B40566F22D95514ADCF9B41;jsessionid=DF8B0486E9633DA06A60222A6311E6A8;jsessionid=387F84A7C5A2CC669F4E8F28A31228AF;jsessionid=E44A8715662803A8A595522643F7EFD6;jsessionid=754949FDBC5354C259EB24C34DD71D34;jsessionid=682A0ED56812596DDFB06E666BAE2186